President Trump signs social media executive order

Salesforce Cuts Revenue, Profit Forecasts; Shares Decline

(Bloomberg) -- Salesforce.com Inc. trimmed its annual revenue and profit forecasts, indicating that the coronavirus-induced recession has weakened demand for the software maker’s cloud applications. Shares declined 4% in extended trading on the news.Sales in fiscal 2021 will be about $20 billion, down from an earlier projection of as much as $21.1 billion, the San Francisco-based company said Thursday in a statement. Analysts, on average, estimated $20.7 billion.The company expects profit, excluding some items, of $2.93 to $2.95 a share, compared with analysts’ projection of $3.14.Chief Executive Officer Marc Benioff, now heading the company solo after co-CEO Keith Block stepped down from his post in February, pledged in March that Salesforce wouldn’t conduct major job cuts for 90 days, and encouraged other CEOs to make the same promise. Earlier this month, the company unveiled software to help businesses safely reopen their offices with systems that manage employees’ shifts and facility cleaning...

AstraZeneca Unveils Data Behind New Win For Blockbuster Drug

(Bloomberg) -- AstraZeneca Plc’s blockbuster drug Tagrisso cut the risk of lung cancer death or relapse by four-fifths over three years, according to detailed results from a study that raises survival prospects for patients in the early stages of the deadly disease.Adding Tagrisso to the regimen of early-stage lung cancer patients who had undergone surgery reduced the risk of dying or disease recurrence by 79%, compared with a placebo, according to the research. Patients’ tumors also had a mutation in a cancer-linked gene, called EGFR. AstraZeneca will present the results at the American Society of Clinical Oncology’s annual conference on Sunday, a month and a half after the trial was halted early because of its strong outcome.Tagrisso is Astra’s biggest product, with sales of $982 million in the first quarter of this year. Around 60,000 additional patients may be eligible for treatment if the drug is approved in early-stage, post-surgical lung...

Will Courts Reverse Earlier Ruling on Amarin Patents? Analyst Weights In

It has been a rough couple of months for pharma company Amarin Corporation (AMRN). At the end of 2019, the cardiovascular health-focused name was flying high after the FDA expanded the labeling for its fish-oil derivative designed to treat high triglycerides, Vascepa. However, seasoned market watchers know that in the world of healthcare investing, all it takes is a single piece of bad news to knock a company off its pedestal.For Amarin, this blow came in the form of an unfavorable verdict on its intellectual property. In March, a district court hit the company with a judgement ruling that invalidated six key patents shielding Vascepa from generic competition on the basis of obviousness.Representing Northland Capital, analyst Carl Byrnes disagrees with the ruling, pointing to several procedural errors as well as a factual error that emerged during the litigation. According to the analyst, the procedural errors included the District Court's conclusion of...